publication date: Mar. 6, 2015

Mark Green, 70, Cancer Center Director

 

Mark Green, former director of Hollings Cancer Center at the Medical University of South Carolina and the University of California, San Diego, Moores Cancer Center, died Feb. 23, at the age of 70.

Green was an important figure in the development of medical oncology and played a pivotal role in the history of both cancer centers.

Green received his MD from Harvard University and trained at Harvard’s Beth Israel Hospital, the NCI and Stanford University. In 1976, he joined UCSD, where he held the Edwin and Evelyn Tasch Chair in Cancer Research and served as director of the UCSD Cancer Center. In 1986, he led the center to its first NCI designation.

In 1996, Green joined MUSC as the director of the Hollings Cancer Center and the Mary M. Gilbreth Professor of Oncology. Serving as director until 2000, he retired from the full-time faculty as professor emeritus in 2004.

A highly respected oncologist, he contributed to the understanding and treatment of solid tumors. His research focused on clinical trials of new therapies for cancers of the lung and pancreas. He was widely published, and his impactful research to improve cancer treatments made a difference in the lives of thousands of cancer patients worldwide.

“Dr. Mark Green was one of the most influential lung cancer medical oncologists in the past 50 years,” commented Gerard Silvestri, the Hillenbrand Professor of Thoracic Oncology at MUSC. “He had a command of the oncologic literature that was second to none. He was one of the few doctors I have known who was not only able to quote chapter and verse about the latest cancer research, but he … Continue reading 41-09 Obituary: Mark Green, 70, Cancer Center Director

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.